Terms: = Ovarian cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
84 results:
1. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract] [Full Text] [Related]
2. [Recurrent Breast cancer with Bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1845-1847. PubMed ID: 38303227
[TBL] [Abstract] [Full Text] [Related]
3. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
4. The promise of combining cdk4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract] [Full Text] [Related]
5. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast cancer.
Brett JO; Mayer EL
Curr Treat Options Oncol; 2023 Jun; 24(6):594-610. PubMed ID: 37060423
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of
Fanta BS; Lenjisa J; Teo T; Kou L; Mekonnen L; Yang Y; Basnet SKC; Hassankhani R; Sykes MJ; Yu M; Wang S
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049714
[TBL] [Abstract] [Full Text] [Related]
7. [Arguments for centralization of surgical treatment of ovarian cancer in France based on morbidity and mortality data].
Meurette J; Daraï E; Tajahmady A; Fouard A; Ducastel A; Collin-Bund V; Jochum F; Lecointre L; Querleu D; Akladios C
Bull Cancer; 2024 Mar; 111(3):239-247. PubMed ID: 36797128
[TBL] [Abstract] [Full Text] [Related]
8. treatment of Breast cancer in Young Adults.
Tesch ME; Partridge AH
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35580291
[TBL] [Abstract] [Full Text] [Related]
9. A Novel cdk4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin treatment in Breast and ovarian cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract] [Full Text] [Related]
10. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract] [Full Text] [Related]
11. New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
[TBL] [Abstract] [Full Text] [Related]
12. lncRNA TPT1‑AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion.
Li H; Jin J; Xian J; Wang W
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34498708
[TBL] [Abstract] [Full Text] [Related]
13. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract] [Full Text] [Related]
14. Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-Myc in ovarian cancer Cells and Tumor Xenograft-Bearing Mice.
Gao Y; Miles SL; Dasgupta P; Rankin GO; Cutler S; Chen YC
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065149
[TBL] [Abstract] [Full Text] [Related]
15. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast cancers.
Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
[TBL] [Abstract] [Full Text] [Related]
16. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.
Xue Z; Lui VWY; Li Y; Jia L; You C; Li X; Piao W; Yuan H; Khong PL; Lo KW; Cheung LWT; Lee VHF; Lee AWM; Tsao SW; Tsang CM
J Exp Clin Cancer Res; 2020 Nov; 39(1):262. PubMed ID: 33243298
[TBL] [Abstract] [Full Text] [Related]
17. Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer.
de Boer R; Hui R; Lim E; Yeo B; Zdenkowski N
Asia Pac J Clin Oncol; 2020 Nov; 16 Suppl 5():3-14. PubMed ID: 33137857
[TBL] [Abstract] [Full Text] [Related]
18. A first-in-class cdk4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L; Tadesse S; Likisa J; Yu M; Noll B; Heinemann G; Lokman NA; Ricciardelli C; Oehler MK; Beck A; Pradhan R; Milne R; Albrecht H; Wang S
Gynecol Oncol; 2020 Dec; 159(3):827-838. PubMed ID: 32958271
[TBL] [Abstract] [Full Text] [Related]
19. cdk4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract] [Full Text] [Related]
20. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
[TBL] [Abstract] [Full Text] [Related]
[Next]
